Drugs / LY3838915
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02632994 | — | cancer | Eli Lilly and Company | Available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3838915 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632994 ↗ |
| Route | Oral | “Administered orally.” NCT02632994 ↗ |